EXEL
Price
$39.04
Change
+$0.35 (+0.90%)
Updated
Sep 26 closing price
Capitalization
10.51B
38 days until earnings call
LQDA
Price
$21.80
Change
-$0.65 (-2.90%)
Updated
Sep 26 closing price
Capitalization
1.88B
45 days until earnings call
Interact to see
Advertisement

EXEL vs LQDA

Header iconEXEL vs LQDA Comparison
Open Charts EXEL vs LQDABanner chart's image
Exelixis
Price$39.04
Change+$0.35 (+0.90%)
Volume$1.64M
Capitalization10.51B
Liquidia
Price$21.80
Change-$0.65 (-2.90%)
Volume$3.72M
Capitalization1.88B
EXEL vs LQDA Comparison Chart in %
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. LQDA commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongBuy and LQDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (EXEL: $39.04 vs. LQDA: $21.80)
Brand notoriety: EXEL: Notable vs. LQDA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 53% vs. LQDA: 124%
Market capitalization -- EXEL: $10.51B vs. LQDA: $1.88B
EXEL [@Biotechnology] is valued at $10.51B. LQDA’s [@Biotechnology] market capitalization is $1.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 2 FA rating(s) are green whileLQDA’s FA Score has 1 green FA rating(s).

  • EXEL’s FA Score: 2 green, 3 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, EXEL is a better buy in the long-term than LQDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 4 TA indicator(s) are bullish while LQDA’s TA Score has 5 bullish TA indicator(s).

  • EXEL’s TA Score: 4 bullish, 4 bearish.
  • LQDA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LQDA is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а -2.64% price change this week, while LQDA (@Biotechnology) price change was -8.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

EXEL is expected to report earnings on Nov 04, 2025.

LQDA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.5B) has a higher market cap than LQDA($1.88B). LQDA YTD gains are higher at: 85.374 vs. EXEL (17.237). EXEL has higher annual earnings (EBITDA): 782M vs. LQDA (-133.4M). EXEL has more cash in the bank: 791M vs. LQDA (173M). EXEL has less debt than LQDA: EXEL (180M) vs LQDA (200M). EXEL has higher revenues than LQDA: EXEL (2.23B) vs LQDA (19.3M).
EXELLQDAEXEL / LQDA
Capitalization10.5B1.88B559%
EBITDA782M-133.4M-586%
Gain YTD17.23785.37420%
P/E Ratio18.77N/A-
Revenue2.23B19.3M11,554%
Total Cash791M173M457%
Total Debt180M200M90%
FUNDAMENTALS RATINGS
EXEL vs LQDA: Fundamental Ratings
EXEL
LQDA
OUTLOOK RATING
1..100
359
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
3220
SMR RATING
1..100
33100
PRICE GROWTH RATING
1..100
5239
P/E GROWTH RATING
1..100
69100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (71) in the Biotechnology industry is in the same range as LQDA (91) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is in the same range as EXEL (32) in the Biotechnology industry. This means that LQDA’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's SMR Rating (33) in the Biotechnology industry is significantly better than the same rating for LQDA (100) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew significantly faster than LQDA’s over the last 12 months.

LQDA's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as EXEL (52) in the Biotechnology industry. This means that LQDA’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's P/E Growth Rating (69) in the Biotechnology industry is in the same range as LQDA (100) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to LQDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELLQDA
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
67%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
64%
Bullish Trend 26 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
53%
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AHSZX20.380.25
+1.24%
Alger Health Sciences Z
GSCYX18.490.18
+0.98%
GuideStone Funds Small Cap Equity Instl
TRTIX22.510.17
+0.76%
T. Rowe Price International Value Eq I
STFBX96.270.34
+0.35%
State Farm Balanced
OEQAX9.98-0.07
-0.70%
Oaktree Emerging Markets Equity A

EXEL and

Correlation & Price change

A.I.dvisor tells us that EXEL and ACLX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and ACLX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.90%
ACLX - EXEL
31%
Poorly correlated
+1.72%
LQDA - EXEL
31%
Poorly correlated
-2.90%
JAZZ - EXEL
30%
Poorly correlated
-0.63%
RIGL - EXEL
29%
Poorly correlated
-0.24%
RVMD - EXEL
28%
Poorly correlated
+3.32%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with MTVA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then MTVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
-2.90%
MTVA - LQDA
44%
Loosely correlated
-2.99%
TPST - LQDA
33%
Poorly correlated
+0.75%
CRNX - LQDA
32%
Poorly correlated
+27.92%
KYMR - LQDA
31%
Poorly correlated
+4.68%
EXEL - LQDA
31%
Poorly correlated
+0.90%
More